SKB535
Solid Tumors
PreclinicalActive
Key Facts
About Klus Pharma
KLUS Pharma is a U.S.-based biotech subsidiary of China's Kelun-Biotech, leveraging its parent company's integrated R&D and manufacturing platforms to advance a diverse pipeline of oncology and non-oncology biologics. The company has built a robust pipeline with multiple clinical-stage assets, most notably in the competitive ADC space, including TROP2 and HER2-targeting candidates. Its strategy combines internal development with strategic partnerships, such as the recent collaboration with Crescent Biopharma, to maximize the global value of its pipeline. KLUS operates as a key bridge for Kelun-Biotech's ambitions in the U.S. and international markets.
View full company profileOther Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| APVO603 | Aptevo Therapeutics | Preclinical |
| APVO711 | Aptevo Therapeutics | Preclinical |
| Platform-derived Immunotherapy | GenCirq | Pre-clinical |
| SP-2-225 | Shuttle Pharmaceuticals | Preclinical |
| SP-1-161 | Shuttle Pharmaceuticals | Preclinical |
| HBM1020 | Harbour BioMed | Phase 1 |
| HBM7022 | Harbour BioMed | Phase 1 |
| HBM9033 | Harbour BioMed | Discovery |
| Undisclosed Whole Cell Vaccine Program(s) | Neuvogen | Pre-clinical |
| SY-5609 | Syros Pharmaceuticals | Phase 1/2 |
| Not Specified (TCR Therapy) | T-Cure Bioscience | Phase 1 |
| B7-H3 Program | Ocean Biomedical | Discovery |